Supplemental material
Leukemia & Lymphoma
Volume 60, 2019 - Issue 10
Original Articles
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis
Jesus G. BerdejaSarah Cannon Research Institute, Nashville, TN, USA; Correspondence[email protected]
http://orcid.org/0000-0003-4362-0376View further author information
http://orcid.org/0000-0003-4362-0376View further author information, Michael C. HeinrichVA Portland Health Care System, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA; http://orcid.org/0000-0003-3790-0478View further author information
http://orcid.org/0000-0003-3790-0478View further author information, , Stuart L. GoldbergJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; http://orcid.org/0000-0002-5996-1055View further author information
http://orcid.org/0000-0002-5996-1055View further author information, , , Jorge CortesMD Anderson Cancer Center, The University of Texas, Houston, TX, USA; http://orcid.org/0000-0002-8636-1071View further author information
http://orcid.org/0000-0002-8636-1071View further author information, , , David RizzieriDuke University School of Medicine, Durham, NC, USA; http://orcid.org/0000-0001-9886-5771View further author information
http://orcid.org/0000-0001-9886-5771View further author information, , Ilva DautajNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA; http://orcid.org/0000-0001-5826-4875View further author information
http://orcid.org/0000-0001-5826-4875View further author information & show all